The Executive Committee on Global Health and Human Security has compiled draft proposals to further promote pharmaceutical and medical device regulatory harmonization in Asia. While the proposals revolve around initiatives for two main pillars - building clinical trial networks and…
HOME > HTA Debates in 2018-2019
HTA Debates in 2018-2019
-
Japan to Roll Out Cost-Effectiveness Assessment Scheme in April
February 21, 2019
-
Importance of Non-ICER Factors in Cost-Effectiveness Assessment Starting to Resonate with Chuikyo Reps
February 7, 2019
-
Tough CEA Rules for Cost-Based Method Products Targeting Imports: EFPIA Japan Vice Chair
February 7, 2019
-
Japan, US, European Trade Groups Give Opinions on Govt’s CEA Proposal: Chuikyo
February 7, 2019
-
PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
-
MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
-
CEFP Finalizes Govt Reform Timeline Urging FY2019 Debate on “Economic Evaluations” for Reimbursement Decisions
December 21, 2018
-
Chuikyo Snubs Industry’s Call to Exclude Listed Products from CEA Scope
December 20, 2018
-
PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations
December 20, 2018
-
Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
-
National Institute of Public Health to Play Core Role in CEA Public Analysis Process
December 6, 2018
-
Chuikyo Agrees on 3 ICER Thresholds for “Tiered” CEA Price Adjustment Model; Industry Hearing Slated by Year-End
December 6, 2018
-
MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront
November 22, 2018
-
MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo
November 22, 2018
-
MOF Panel Urges Govt to Use Economic Evaluations for Reimbursement Decisions: FY2019 Budget Recommendation
November 21, 2018
-
Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
-
Experts Say ICER Deduction Unscientific, MHLW Proposes Different Thresholds for Cancer and Orphan Drugs
November 8, 2018
-
Chuikyo Supports Price Raise Rules for Cost-Effective Products
November 8, 2018
-
MHLW Pitches “Tiered Model” for CEA Price Tweak, but Faces Chuikyo Opposition
November 8, 2018
-
Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…